Informations générales (source: ClinicalTrials.gov)

NCT03866863 Statut inconnu
Intra Uterine Growth Restriction. Minimum Required Evidence-based Care and Neonatal Prognosis: Impact of Healthcare Pathways (IUGR)
Observational
  • Retard de croissance intra-utérin
Hospices Civils de Lyon (Voir sur ClinicalTrials)
septembre 2018
avril 2019
29 juin 2024
Intrauterine growth restriction (IUGR) is associated with an increase in perinatal mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular and endocrine complications. In Europe, about 400,000 pregnancies per year are complicated by IUGR. However, antenatal diagnosis seems insufficient in clinical practice, making it impossible to recognize up to 75% of foetuses with IUGR. At a time when the use of good clinical practice has demonstrated a significant improvement in neonatal survival without severe morbidity, foetuses with IUGR are less likely to receive optimal care. Our hypothesis is that the rate of IUGR diagnosed underestimates the rate of actual IUGR.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Hôpital Femme Mère Enfant - Bron - France Muriel Doret, Prof. En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital
Femme-Mère-Enfant

- from 1st of january 2011 to 31 december 2017.


- Infants born out of the hospital and secondarily hospitalized in the hospital
Femme-Mère-Enfant .

- Multiple pregnancies,

- children with congenital fetal anomalies

- pregnancies without first trimester ultrasound (to date the pregnancy)